Please login to the form below

Is the world ready for a COVID-19 vaccine?

At the beginning of November, Pfizer and BioNTech announced that their vaccine candidate was more than 90% effective at preventing COVID-19 infection. Since then, other good news has followed, with collaborations, including Moderna and AstraZeneca, publishing similarly positive results. This is a phenomenal feat that would have been unimaginable just one year ago. But a vaccine is only as effective as its deployment and uptake. There should be no doubt that as soon as the first COVID-19 vaccine was approved, a very difficult logistics game ensued. The reality is that a COVID-19 vaccine will present a whole new unfamiliar set of operational challenges. There are currently more than 170 candidate vaccines in development, each with its own benefits and each with its own challenges. Here, we explore some of those challenges and reflect on what must be considered by health systems and governments to set us on track towards pandemic recovery.

By Shannon Lacombe, Hanover Health

At the beginning of the coronavirus pandemic, Dr Tedros Adhanom Ghebreyesus, Director General of the World Health Organization (WHO), dramatically told a G20 Leaders’ Summit that “we are at war with a virus that threatens to tear us apart.” At the same meeting, António Guterres, UN General Secretary, said “we are at war with a virus – and not winning it... this war needs a war-time plan to fight it”.

While there has been contention and debate about the appropriateness of the wartime analogy, it does seem to work to describe the unprecedented scale and effort required to sequester and defeat this virus. And while not military strategists, we can speculate that any “war-time plan” should be made up of a number of parts and that its success is reliant on the sum of those parts. In this case, a significant component is the successful development and roll out of a COVID-19 vaccine.

At the beginning of November, Pfizer and BioNTech announced that their vaccine candidate was more than 90% effective at preventing COVID-19 infection, based on initial results from their ongoing Phase 3 clinical trial. While the roll out of this vaccine still requires approvals by many national regulatory agencies, at the time of writing, both the UK and Canada had moved ahead with authorizations of the vaccine. Furthermore, the companies stated they could have as many as 50 million doses produced by the end of 2020 and 1.3 billion doses by the end of 2021. Since this initial announcement, other good news in vaccine development has followed, with companies and collaborations, including Moderna and the AstraZeneca/University of Oxford team, publishing similarly positive trial results.

This is a phenomenal feat and one which would have been largely unimaginable just one year ago. Vaccines pass through multiple stages of development and in normal times, it wouldn’t be unusual for the process to take 10–15 years. In COVID-19 times, this process has taken less than 12 months.

It is one of the greatest breakthroughs in modern medicine to have developed a vaccine in this timescale. But a vaccine is only as effective as its deployment and uptake. There should be no doubt that as soon as the first COVID-19 vaccine was approved, a very difficult logistics game ensued. The reality is that a COVID-19 vaccine will present a whole new unfamiliar set of operational challenges.

In the situation where the vaccine gets to everyone who would benefit from it, millions of doses will need to travel hundreds, if not thousands, of miles from manufacturers to hospitals, to general practices and pharmacies, which in turn must store, track and eventually administer the vaccines. This isn’t completely new territory; organisations such as the Centers for Disease Control and Prevention (CDC) in the United States, which distributed flu vaccines during the 2009 H1N1 pandemic with the help of local organisations, manage the roll out of routine immunisations every day.

A few of the coronavirus vaccines being trialled use “messenger” RNA (mRNA) technology. While this novel vaccine technology has never received approval before, it looks like it may be one of a few optimal and innovative immunisation approaches. After injection into muscle, the synthetic mRNA is taken up by cells and the cell’s machinery reads it to make a surface protein of the SARS-CoV-2 virus, called the “spike protein”. The rest of the process is identical to that used by other vaccines, where the immune system mounts a response by recognising the viral protein as foreign and develops antibodies against it.

One of the reasons these vaccines have progressed so quickly to, and through, clinical trials is because they are the fastest to make and manufacture. Within weeks, clinical batches can be generated through a process that is cell-free and scalable. However, on the flip side, these vaccines may also be the slowest or most difficult to deploy. While they rely on a technology whose central advantage hinges on rapidity of manufacture, its downfall is extreme physical fragility.

These first mRNA vaccines must be frozen at extremely low temperatures, and once thawed, will stay intact for only a short period of time. Furthermore, these vaccines must be given in two separate doses, administered weeks apart and both doses must come from the same manufacturer. This means that vaccine administration will require careful record tracing and tracking, which may be less of a challenge in a single-payer health system, but poses a whole set of challenges for countries and states that do not have immunisation registries or ways of tracking patients. In time, some of these challenges may be overcome, for example, if the technology used for mRNA vaccines advances to allow them to be stored at higher temperatures. However, the novelty of these vaccines means that even the manufacturers are still figuring out these challenges.

Another, and perhaps grander, challenge is one of global vaccine equity and reducing inequalities in access. One of the ways the world is looking to mitigate this is through the COVAX initiative, which is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), the Global Alliance for Vaccines and Immunisation (GAVI) and the WHO. COVAX is a multinational collaborative platform that is supporting the research, development and manufacturing of a wide range of COVID-19 vaccine candidates. All participating countries, regardless of income levels, will have equal access to these vaccines once they are developed. The initial aim is to have 2 billion doses available by the end of 2021, which should be enough to protect high-risk and vulnerable people, as well as frontline healthcare workers. Without the successful implementation of COVAX, there is a very real risk that the majority of people in the world would go unprotected against COVID-19 and the pandemic would continue to wreak havoc.

To have a truly effective prevention approach, first we need COVID-19 vaccines that are both safe and effective; we then need these to be manufactured at scale; and finally, we need them to be deployed effectively and to all corners of the world. Of course, another key piece of an effective vaccination roll-out is being able to communicate to the public about all of these aspects of a complicated topic.

The above is not an exhaustive list but should illustrate that this is not going to be a straightforward exercise. While a lot of the messaging around ending the pandemic has been reliant on the success of a vaccine, this does not mean that once a vaccine has arrived, the pandemic is over. There are still a lot of kinks to work out and a lot of challenges to overcome. The development of an effective vaccine remains truly a phenomenal feat, but it is only step one, and the healthcare industry would be doing the world a disservice if it did not acknowledge that.

It is also critical to understand that a vaccine is not the only piece to the pandemic puzzle. Whilst it remains one of the components (albeit a key one), there are other key components, including effective therapeutics and lifestyle interventions – all of which will play their part in our success.

There are currently more than 170 candidate vaccines in development, each with its own benefits and each with its own challenges. Where one vaccine may be more stable and easier to store, another may be more effective in older people, and another may require fewer doses. We are on the cusp of modern medicine’s most impressive influx of innovation and the first wave of vaccines are certainly not going to be the only important ones.

To end with the contentious war-time analogy – we may be well on our way to winning this battle, but we are still fighting a war. All of us—across industry, advocacy organisations and policymakers—have some more time ahead of us in the trenches before we can claim ourselves victorious.

As companies continue to publish positive results from vaccine trials, it will be critical for the pharmaceutical sector, advocacy organisations, and decision makers, to consider how to ensure all of those that will benefit most urgently from a vaccine, receive it. As healthcare policy specialists, we must work to support organisations and stakeholders during this time to navigate a complex and evolving landscape.

To further explore how we can support companies and advocacy partners during this complex time, please contact us.

18th December 2020


Company Details

Hanover Communications

+44 (0)20 7400 4480

Contact Website

Riverside House
Southwark Bridge House
United Kingdom

Latest content on this profile

Innovative contracting at the top of the market access agenda
Value-based contracting (VBC) is firmly on the market access agenda across Europe and there are converging views on what is needed in this space.  Pharma and biotech, patients, payers, regulators and HTA agencies gathered at the World Evidence, Pricing and Access Congress in March to discuss challenges and potential solutions. Hanover hosted a discussion about experiences of VBC and where changes are needed. We explored whether a global archetype approach could support in-country negotiating agreements.   In their latest blog, Hanover Health’s Emma Eatwell and Josie Godfrey explore what the future for VBC might look like.
Hanover Communications
The future of nanomedicine regulation
With the EU’s upcoming revision of the general pharmaceutical legislation, the bloc has the chance to provide long-awaited clarity around the future of nanomedicine. And just as important, it will give the EU a chance to lead on a conversation around the needed regulatory framework for nanomedicines as other countries -including the US- currently struggle with this. In their latest blog, Hanover Brussels Alicia Rojo Santos and Pilar Serrano explores why the sector expecting to set off following the success of the Pfizer and Moderna SARS-CoV-2 vaccines is more important than ever.
Hanover Communications
Getting it Right First Time: Building a Value-Based Contract Strategy
In their latest blog, Hanover Brussels Emma Eatwell and Josie Godfrey will explore how companies can efficiently and effectively increase the chances of securing value-based contracts that work for all.
Hanover Communications
The role of pharma in breaking through the backlog
As health systems emerge from the pandemic, and attention turns to the backlog of patients waiting for treatment, how can the pharmaceutical industry position itself as part of the solution? In his latest blog, Hanover Health’s Alexander Davies looks to answer the following questions – big pharma was there for the world when it needed vaccines in record-breaking time, can it find the innovations that we need now to clear through the queue of people waiting for treatment? Can it partner with health systems to speed up access, improve patient outcomes and reduce the burden on healthcare professionals? And, if it did so, what are the opportunities for its reputation?
Hanover Communications
Cardiovascular disease: The scale of the challenge
Many years in the making, the first CVDPREVENT audit report, published recently, gives a detailed snapshot of how those with cardiovascular diseases (CVD) are identified, diagnosed, and managed across England. In his latest blog, Hanover Health’s Mark MacDonald asks – what does this data tell us about the impact CVD is having on our collective health, how much are health inequalities a factor, and where are the opportunities for the system to collectively do better to prevent disease, disability, and death?
Hanover Communications
Cancer: Beyond the Backlog
With the recent performance of Cancer Waiting Times the worst on record, and predictions of thousands of ‘missing’ cancer patients that have yet to enter the system, Hanover’s Health’s Emma Greenwood asks – how do we get back to that transformation agenda and move beyond the backlog?
Hanover Communications